Literature DB >> 30229849

Protective effect of ulinastatin combined with dexmedetomidine on lung injury after cold ischemia-reperfusion in rats.

G Wang1, J-Y Li, Y-Q Weng, M Ding, H-L Yu, Q Wang, H-C Ren, R-B Xu, W-L Yu.   

Abstract

OBJECTIVE: We investigated the protective effect of ulinastatin combined with dexmedetomidine on lung injury after hepatic ischemia-reperfusion in rats.
MATERIALS AND METHODS: A total of 60 healthy and clean male Sprague Dawley (SD) rats were divided into the blank control group (group O), the model control group (group K), the ulinastatin and dexmedetomidine group (group F) according to random number table with 20 rats in each group.
RESULTS: The plasma concentrations of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8) and malondialdehyde (MDA) at T1, T2 and T3 time points in rats of the three groups were significantly higher than those of the T0 time point (p<0.05). The superoxide dismutase (SOD) activity in the plasma of rats of the three groups was significantly lower at T1, T2 and T3 time point when compared with that of T0 (p<0.05). The concentrations of TNF-α, IL-6, IL-8 and MDA in group K at T1, T2 and T3 moments were significantly higher than those of group O (p<0.05). However, the concentrations of IL-6, IL-8, TNF-α and MDA in group F at T1, T2, T3 were significantly lower than those of group K (p<0.05). The activities of SOD in group K at T1, T2, T3 were all significantly higher than those of group O (p<0.05). Meanwhile, the activities of SOD in group F at T1, T2, T3 were significantly higher than those of group K (p<0.05).
CONCLUSIONS: Ulinastatin combined with dexmedetomidine can reduce the inflammatory response and inhibit lipid peroxidation, eventually alleviating acute lung injury after hepatic ischemia-reperfusion in rats.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30229849     DOI: 10.26355/eurrev_201809_15839

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  2 in total

Review 1.  Research progress of ulinastatin in the treatment of liver diseases.

Authors:  Shangping Fang; Pengfei Li; Chenxu Zhu; Xiaoxiao Han; Pengju Bao; Wenjun Guo
Journal:  Int J Clin Exp Pathol       Date:  2020-11-01

2.  Effects of Ulinastatin on Myocardial Ischemia-Reperfusion Injury, Cardiac Function, and Serum TNF-α and IL-10 Levels in Patients Undergoing Cardiac Valve Replacement under Cardiopulmonary Bypass.

Authors:  Hai Wang; Dafa Zhang; Hongbo Qian; Jun Nie; Jun Wei
Journal:  Comput Math Methods Med       Date:  2022-04-01       Impact factor: 2.238

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.